The German consulting firm Inno AG built on the results of NERA and extrapolated the proportion of indirect savings calculated by them for the whole German import relevant market. To obtain this, they subtract those medicines with generic competition and those without import alternative from the total market for prescription-only preparations. Indirect savings in Germany in 2018 amounted to €2.6 billion.